Nemus Bioscience, Inc. (OTCMKTS:NMUS) Corporate Logo

NEMUS BIOSCIENCE INC (OTCMKTS:NMUS) reported an increase of 197.16% in shorted shares. FINRA announced shorted shares of NMUS’s total 135,800 shares. That’s 197.16% up from 45,700 shares. 0 days will cost NMUS with 1.63 million average volume to recover its former position.

The stock decreased 2.47% or $0.01 during the last trading session, hitting $0.395.Nemus Bioscience, Inc. has volume of 84,849 shares. Since January 10, 2018 NMUS has 0.00% and is . NMUS the S&P 500 by 0.00%.

Nemus Bioscience, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of cannabinoid therapeutics.The firm is valued at $52.89 million. The companyÂ’s product candidates in preclinical stage include NB1111 for the treatment of glaucoma; NB1222 used for treating chemotherapy induced nausea and vomiting; and NB3111 for the treatment of methicillin-resistant staphylococcus aureus.Last it reported negative earnings. The Company’s products under research comprise NB2111 for use in treating chemotherapy induced peripheral neuropathy; and NB2222 for the treatment of uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *